Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Matthew James Butler"'
Autor:
Srikanth R. Polusani, Hongxin Fan, Marsha C. Kinney, Javier Esparza, Huynh Nga Nguyen, Matthew James Butler, Samy L. Habib, Gopalrao V.N. Velagaleti, Edward A. Medina, Valerie Cortez, Babatunde O. Oyajobi, Reto Asmis
Publikováno v:
Int J Cancer
Proteasome inhibitor (PI) therapy has improved the survival of multiple myeloma (MM) patients. However, inevitably, primary or acquired resistance to PIs leads to disease progression; resistance mechanisms are unclear. Obesity is a risk factor for MM
Autor:
Adolfo Enrique Diaz Duque, Anand Karnad, Matthew James Butler, Elizabeth Bowhay-Carnes, Joel E Michalek, Gabriela Huelgas, Ricardo Aguiar
Publikováno v:
Blood. 140:6610-6611
Publikováno v:
Blood. 140:5025-5026
Autor:
Eun-Ang Rabier-Moreau, James Hadfield, Guillem Portella, Matthew James Butler, Yves Konigshofer
Publikováno v:
Regular and young investigator award abstracts.
Background Tumor mutational burden (TMB), as measured by exome or panel sequencing of tumor tissue (tTMB) or blood (bTMB), has been identified as a potential predictive biomarker for treatment benefit in patients with various cancer types receiving i
Publikováno v:
Trends in Cancer. 3:871-882
The effective deployment of rationally developed therapies for diffuse large B cell lymphoma (DLBCL) requires rapid assimilation of new biological data. Within this framework, here we address topical issues at the intersection of DLBCL biology and th
Publikováno v:
Southern Medical Journal. 109:282-289
Objectives Survival of patients with multiple myeloma (MM) has improved as a result of therapeutic advances. There is evidence that some patients with MM develop pulmonary hypertension (PH). The objective of this study was to identify risk factors of
Publikováno v:
Blood. 134:1592-1592
R-CHOP remains the standard therapy for diffuse large B cell lymphoma (DLBCL), even though long-term disease free survival is achieved in only ~60-70% of the patients. One approach to improve on this cure rate is to implement rationally devised thera
Autor:
Matthew James Butler, Feras M. Hantash, Alexander F. Lovejoy, Li Liu, Keith M. Gligorich, Maria E. Arcila, Bharathi Anekella, Christian Gloeckner, Yves Konigshofer, Ravindra Kohle, Chen Zhao, Russell Garlick, Omoshile Clement, Carrie Sougnez, Ahmet Zehir, Niall J. Lennon, Anthony Martin Magliocco
Publikováno v:
Journal of Clinical Oncology. 37:e14746-e14746
e14746 Background: Next Generation Sequencing based assays are designed to detect genomic aberrations in a limited number of target regions. However, there is a need for accurate measurement of tumor mutational burden (TMB) as low as 4 to as high as
Autor:
Shu-Jen Chen, Victor J Weigman, Chen Zhao, Arnaud Papin, Matthew James Butler, Laura E. MacConaill, Vincent Funari, David Fabrizio, Ahmet Zehir, Aparna Pallavajjala, Diana M. Merino, Jeffrey M. Conroy, Ruchi Chaudhary, Paul M. Williams, Wangjuh Sting Chen, Matthew D. Hellmann, Mark Sausen, Lisa M. McShane, Mingchao Xie
Publikováno v:
Journal of Clinical Oncology. 37:2624-2624
2624 Background: Tumor mutational burden (TMB) is a predictive biomarker of response to immune checkpoint inhibitors across multiple cancers. In Phase 1 of the Friends of Cancer Research Harmonization Project, we demonstrated a robust correlation bet
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:S145-S146